BSA Conjugated Gastric Inhibitory Polypeptide (GIP) 
Incretin hormone; Glucose Dependent Insulinotropic Peptide
Overview
Properties
- Product No.CPA882Mu11
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
-
Applications
Immunogen; SDS-PAGE; WB.
If bio-activity of the protein is needed, please check active protein.
Research use only - DownloadInstruction Manual
- CategoryEndocrinologyGastroenterologyHormone metabolism
- SourceProtein Conjugation
- Original Molecular Massn/a
- Buffer FormulationPBS, pH7.4.
- Traits Freeze-dried powder, Purity > 90%
- Isoelectric Pointn/a
Share your citation
Upload your experimental result
Review
Leave a message
Loading...
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Please attach serial No. on instruction manual
Contact us
Please fill in the blank.
Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code*
-
Packages (Simulation)
-
Packages (Simulation)
-
Mass spectrometry
-
-
ISO9001: 2008, ISO13485: 2003 Registered
Formula
Usage
Reconstitute in PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
Storage
Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.
Stability
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
Increment services
Citations
- The anti-hyperglycemic efficacy of a lipid-lowering drug Daming capsule and the underlyingsignaling mechanisms in a rat model of diabetes mellitus.pubmed:27721485
- The Effects of Duodenojejunal Omega Switch in Combination with High-Fat Diet and Control Diet on Incretins, Body Weight, and Glucose Tolerance in Sprague-Dawley Rats.pubmed:28840471
- Preserving Duodenal-Jejunal (Foregut) Transit Does Not Impair Glucose Tolerance and Diabetes Remission Following Gastric Bypass in Type 2 Diabetes Sprague …Pubmed:29098544
- Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity
- Low AS160 and high SGK basal phosphorylation associates with impaired incretin profile and type 2 diabetes in adipose tissue of obese patientsPubmed: 31734225
- The Leading Role of Peptide Tyrosine Tyrosine in Glycemic Control After Roux-en-Y Gastric Bypass in RatsPubmed: 31701411
- Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetesPubmed:35251693